Euroopa Liit - eesti - EMA (European Medicines Agency)

gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - suguhormoonid ja genitaalsüsteemi, - oral contraceptive.

Euroopa Liit - eesti - EMA (European Medicines Agency)

estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - suguhormoonid ja genitaalsüsteemi, - suukaudne kontratseptsioon. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , kolmekordne kombineeritud ravi) lisandina toitumise ja treeningu patsientidel, ebapiisavalt kontrollitud nende maksimaalne talutav annus metformiin ja sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Eesti - eesti - Ravimiamet

tubilux pharma s.p.a - pilokarpiin - silmatilgad, lahus - 20mg 1ml 10ml 1tk

Eesti - eesti - Ravimiamet

s.a.l.f. laboratorio farmacologico s.p.a. - isoprenaliin - süstelahus - 0,2mg 1ml 1ml 5tk

Eesti - eesti - Ravimiamet

hikma italia s.p.a. - dopamiin - infusioonilahuse kontsentraat - 40mg 1ml 5ml 10tk

Eesti - eesti - Ravimiamet

monico spa - isoprenaliin - süstelahus - 0,2mg 1ml 1ml 5tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international nv - bosentan (as monohydrate) - hypertension, pulmonary; scleroderma, systemic - muud antihypertensives - ravi pulmonaalse arteriaalse hüpertensiooni (pah) parandada koormustaluvust ja maailma terviseorganisatsiooni (who) iii funktsionaalse klassi patsientidel sümptomid. efektiivsust on näidatud:primaarse (idiopaatilise ja perekondlik) pah;pah teisejärguline skleroderma ilma märkimisväärse interstitsiaalne kopsuhaigus;pah seotud kaasasündinud süsteemne--suhu lükkab ja eisenmenger ' füsioloogia. mõned täiustused on ka näidanud patsientidel pah who funktsionaalse klassi ii. stayveer on ka märgitud arvu vähendada uue digitaalse haavandid patsientidel süsteemne multiplex ja pidev digital-haavand haigus.

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , kolmekordne kombineeritud ravi) lisandina toitumise ja treeningu patsientidel, ebapiisavalt kontrollitud nende maksimaalne talutav annus metformiin ja sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.